ABL Bio's gastric cancer drug Givastomig shrinks tumors by 79%, advancing phase 3 preparations
Predicted impact: Medium
Same Givastomig 79% tumor shrinkage data already reported; phase 3 prep is incremental.
ABL Bio에이비엘바이오
298380 · KOSDAQ · ₩298380 · 에이비엘바이오
₩40,850▲ ₩50 (0.12%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −56.73%
- Market cap
- ₩2.3T
- Enterprise value
- ₩2.1T
- P/E
- —
- P/B
- 13.3×
- Dividend yield
- 0.0%
- ROE
- −45.9%
- Net margin
- −229.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−84.1% from the high
₩39,700Today: ₩40,450 – ₩42,600₩257,500
Returns
- 1W−8.6%
- 1M−19.6%
- 3M−40.6%
- 6M−70.7%
- YTD−79.6%
- 1Y−56.7%
- Volume today
- 247,332
- 0.7× the 20-day average
- Traded today
- ₩10B
- Listed shares
- 55,987,463
- EPS (12 months)
- −₩1,404
- Earnings yield −3.4%
AI research · InitiationABL Bio: Loss-making KOSDAQ biotech with shares down 51.4% over one yearThe data shows a loss-making biotech with irregular revenue, a moderate balance sheet and a sharp share price decline.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headlines report strong trial results and progress toward late-stage testing. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-20.1% over the last month; the price is below its 20-day average.
- News impactSome8 news items and filings in two weeks; 0 rated high impact, 4 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 27: buy ₩772M at the close (5.1% of 20-day average trading value)
On its 32 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 14.0% of trading value and pointed the same way 26 of 32 times.
- 2× KODEX KOSDAQ150 Leverage ₩630M
- 2× TIGER KOSDAQ150 Leverage ₩75M
- -1× KODEX KOSDAQ150 Futures Inverse ₩44M
- 2× RISE KOSDAQ150 Futures Leverage ₩13M
- 2× KIWOOM KOSDAQ150 Futures Leverage ₩3.3M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.9%
- KODEX KOSDAQ150 Leverage2×0.9%
- TIGER KOSDAQ1500.9%
- RISE KOSDAQ1500.9%
- TIGER KOSDAQ150 Leverage2×0.9%
- ACE KOSDAQ 1500.9%
- KIWOOM KOSDAQ1500.9%
- SOL KOSDAQ1500.9%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 41,150
Basis +0.73% · implied rate +16.7%
Open interest 8,599 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
ABL Bio stock overview
ABL Bio (에이비엘바이오, KRX: 298380) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops biopharmaceuticals based on its proprietary bispecific antibody platform, Grabody, and generates revenue mainly by out-licensing its pipeline programs to global pharmaceutical partners in exchange for upfront fees, milestones and royalties. Its shares closed at ₩40,850 on Oct 27, 2026, up 0.12% on the day, giving it a market value of ₩2.3T.
Key facts
- Market cap
- ₩2.3T
- Sector
- Biotech & Pharma
- Latest price change
- +0.12%
- As of
- Oct 27, 2026
- Main business
- The company develops biopharmaceuticals based on its proprietary bispecific antibody platform, Grabody, and generates revenue mainly by out-licensing its pipeline programs to global pharmaceutical partners in exchange for upfront fees, milestones and royalties.
Quick answers about ABL Bio
- What does ABL Bio do?
- The company develops biopharmaceuticals based on its proprietary bispecific antibody platform, Grabody, and generates revenue mainly by out-licensing its pipeline programs to global pharmaceutical partners in exchange for upfront fees, milestones and royalties. S. subsidiary NEOK Bio.
- What is the market cap of ABL Bio?
- The market capitalisation of ABL Bio was ₩2.3T at the close on Oct 27, 2026.
- Who are the largest shareholders of ABL Bio?
- According to the latest official filings, the largest reported holders are LEESANGHOON (24.53%, as of Oct 16, 2026); National Pension Service (4.02%, as of Apr 1, 2026); Lee Jae-cheon (1.41%, as of Feb 28, 2025).
- When is the next earnings report from ABL Bio?
- Korean companies rarely announce results dates in advance. Based on when ABL Bio filed the same report in past years, its next 3q results is expected between Nov 10, 2026 and Nov 12, 2026.
- Does the National Pension Service own ABL Bio?
- Yes. The National Pension Service held 4.02% of ABL Bio shares as of Apr 1, 2026.
Company profile
The company develops biopharmaceuticals based on its proprietary bispecific antibody platform, Grabody, and generates revenue mainly by out-licensing its pipeline programs to global pharmaceutical partners in exchange for upfront fees, milestones and royalties. Its focus areas include bispecific immuno-oncology drugs, antibody-drug conjugates (ADCs) and neurodegenerative disease treatments, with ADC clinical development handled by its U.S. subsidiary NEOK Bio. The company relies on contract research and manufacturing partners for large-scale antibody production and has no commercial product sales.
Written by AI from the company's latest annual report.
- Korean name
- 에이비엘바이오
- Sector
- Biotech & Pharma
- CEO
- 이상훈
- Founded
- Feb 2016
- Listed
- Dec 2018
- Listed shares
- 55,987,463
- Fiscal year ends
- Month 12
- Website
- www.ablbio.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
ABL Bio's gastric cancer candidate shows tumor reduction in 79% of treated patients
Predicted impact: Medium
Clinical data on ABL111 already covered at ESMO this fortnight; 79% tumor reduction restates it.
ABL Bio Announces Additional Clinical Data for ABL111 and ABL503, Pushes Ahead with Follow-on Development
Predicted impact: Low
ESMO clinical data presentation already announced in the last 14 days.
Recent filings
See all- 5%+ holding reportOct 16, 2026
- 5%+ holding reportSep 4, 2026
- [Amended] Notice of Stock Purchase Option GrantAug 31, 2026
- Notice on Grant of Stock Purchase OptionsAug 26, 2026
- Half-year report (Jun 2026)Aug 11, 2026
Titles in Korean until English translations are added.
Also known as: ABL Bio / 에이비엘바이오 / 298380 / KRX:298380
Source: KRX statistical information